{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T14:57:02Z","timestamp":1790607422591,"version":"4.1.0"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T00:00:00Z","timestamp":1790553600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T00:00:00Z","timestamp":1790553600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Breast Cancer Res Treat"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1007\/s10549-026-08090-5","type":"journal-article","created":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T14:11:20Z","timestamp":1790604680000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Dermatologic adverse events associated with Sacituzumab Govitecan: an international retrospective study from the EADV Task Force \u201cDermatology for Cancer Patients\u201d and pharmacovigilance analysis"],"prefix":"10.1007","volume":"219","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1156-7139","authenticated-orcid":false,"given":"Ioannis-Alexios","family":"Koumprentziotis","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Cawley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elliot","family":"Ewig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandre O.","family":"G\u00e9rard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ma\u00eblys","family":"Labat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gra\u017cyna","family":"Kami\u0144ska-Winciorek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcin","family":"Kubeczko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca","family":"Rapparini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michela","family":"Starace","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katerina","family":"Grafanaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Kamaratou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dimitrios","family":"Mavroudis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Katoulis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vasiliki","family":"Nikolaou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kara","family":"Heelan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dimitra","family":"Koumaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,28]]},"reference":[{"issue":"10","key":"8090_CR1","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.1007\/s40265-020-01337-5","volume":"80","author":"YY Syed","year":"2020","unstructured":"Syed YY (2020) Sacituzumab Govitecan: First Approval. Drugs 80(10):1019\u20131025","journal-title":"Drugs"},{"issue":"8","key":"8090_CR2","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1080\/14737140.2019.1654378","volume":"19","author":"J Weiss","year":"2019","unstructured":"Weiss J, Glode A, Messersmith WA, Diamond J (2019) Sacituzumab govitecan: breakthrough targeted therapy for triple-negative breast cancer. Expert Rev Anticancer Ther 19(8):673\u2013679","journal-title":"Expert Rev Anticancer Ther"},{"issue":"8","key":"8090_CR3","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1056\/NEJMoa1814213","volume":"380","author":"A Bardia","year":"2019","unstructured":"Bardia A, Mayer IA, Vahdat LT et al (2019) Sacituzumab Govitecan-hziy in Refractory Metastatic Triple-Negative Breast Cancer. N Engl J Med 380(8):741\u2013751","journal-title":"N Engl J Med"},{"issue":"16","key":"8090_CR4","doi-asserted-by":"publisher","first-page":"1529","DOI":"10.1056\/NEJMoa2028485","volume":"384","author":"A Bardia","year":"2021","unstructured":"Bardia A, Hurvitz SA, Tolaney SM et al (2021) Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer. N Engl J Med 384(16):1529\u20131541","journal-title":"N Engl J Med"},{"issue":"10411","key":"8090_CR5","doi-asserted-by":"publisher","first-page":"1423","DOI":"10.1016\/S0140-6736(23)01245-X","volume":"402","author":"HS Rugo","year":"2023","unstructured":"Rugo HS, Bardia A, Marm\u00e9 F et al (2023) Overall survival with sacituzumab govitecan in hormone receptor-positive and human epidermal growth factor receptor 2-negative metastatic breast cancer (TROPiCS-02): a randomised, open-label, multicentre, phase 3 trial. Lancet 402(10411):1423\u20131433","journal-title":"Lancet"},{"issue":"12","key":"8090_CR6","doi-asserted-by":"publisher","first-page":"3709","DOI":"10.1038\/s41591-024-03269-z","volume":"30","author":"B Xu","year":"2024","unstructured":"Xu B, Wang S, Yan M et al (2024) Sacituzumab govitecan in HR+HER2- metastatic breast cancer: the randomized phase 3 EVER-132-002 trial. Nat Med 30(12):3709\u20133716","journal-title":"Nat Med"},{"issue":"19","key":"8090_CR7","doi-asserted-by":"publisher","first-page":"1912","DOI":"10.1056\/NEJMoa2511734","volume":"393","author":"J Cort\u00e9s","year":"2025","unstructured":"Cort\u00e9s J, Punie K, Barrios C et al (2025) Sacituzumab Govitecan in Untreated, Advanced Triple-Negative Breast Cancer. N Engl J Med 393(19):1912\u20131925","journal-title":"N Engl J Med"},{"issue":"6","key":"8090_CR8","doi-asserted-by":"publisher","first-page":"1177","DOI":"10.1016\/j.jaad.2024.08.036","volume":"91","author":"C Gronbeck","year":"2024","unstructured":"Gronbeck C, Hadfield MJ, Grant-Kels JM (2024) Dermatologic toxicities of antibody-drug conjugates. J Am Acad Dermatol 91(6):1177\u20131188","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"8090_CR9","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1007\/s40257-024-00847-2","volume":"25","author":"A Belzer","year":"2024","unstructured":"Belzer A, Pach JJ, Valido K, Leventhal JS (2024) The Impact of Dermatologic Adverse Events on the Quality of Life of Oncology Patients: A Review of the Literature. Am J Clin Dermatol 25(3):435\u2013445","journal-title":"Am J Clin Dermatol"},{"key":"8090_CR10","doi-asserted-by":"publisher","first-page":"1276976","DOI":"10.3389\/fonc.2023.1276976","volume":"13","author":"X Gui","year":"2023","unstructured":"Gui X, Zhao J, Ding L et al (2023) Assessing real-world safety concerns of Sacituzumab govitecan: a disproportionality analysis using spontaneous reports in the FDA adverse event reporting system. Front Oncol 13:1276976 Published 2023 Oct 6","journal-title":"Front Oncol"},{"key":"8090_CR11","unstructured":"European Academy of Dermatology and Venereology (EADV) Task force dermatology for cancer patients. Available from: https:\/\/eadv.org\/about-eadv\/task-forces\/dermatology-for-cancer-patients\/. Last Accessed 29\/08\/2026."},{"key":"8090_CR12","volume-title":"National Institutes of Health, National Cancer Institute. Common terminology criteria for adverse events (CTCAE) version 5.0","author":"U.S. Department of Health and Human Services","year":"2017","unstructured":"U.S. Department of Health and Human Services (2017) National Institutes of Health, National Cancer Institute. Common terminology criteria for adverse events (CTCAE) version 5.0. National Cancer Institute, Bethesda"},{"issue":"6","key":"8090_CR13","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1016\/j.therap.2019.09.004","volume":"50","author":"N Moore","year":"1995","unstructured":"Moore N, Noblet C, Kreft-Jais C, Lagier G, Ollagnier M, Imbs JL (1995) La banque de cas du syst\u00e8me fran\u00e7ais de pharmacovigilance: quelques exemples d\u2019exploitation [French pharmacovigilance database system: examples of utilisation]. Therapie 50(6):557\u2013562","journal-title":"Therapie"},{"issue":"4","key":"8090_CR14","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1016\/S1246-7820(99)80036-6","volume":"6","author":"A Spreux","year":"1999","unstructured":"Spreux A, Baldin B, Chichmanian RM (1999) La pharmacovigilance en pratique [Pharmacovigilance in practice]. Transfus Clin Biol 6(4):254\u2013259","journal-title":"Transfus Clin Biol"},{"key":"8090_CR15","unstructured":"World Health Organization (WHO) & Uppsala Monitoring Centre (UMC) VigiBase: The WHO global individual case safety report database. Uppsala, Sweden. Available from: https:\/\/who-umc.org\/vigibase-data-access\/about-vigibase\/. Last Accessed 25\/08\/2026."},{"issue":"6","key":"8090_CR16","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1007\/s40264-025-01642-6","volume":"49","author":"JS Brand","year":"2026","unstructured":"Brand JS, Gauffin O, Sartori D et al (2026) VigiBase: Resource Profile Update with a Summary of Global Patterns and Trends in Adverse Event Reports for Medicines and Vaccines. Drug Saf 49(6):613\u2013629","journal-title":"Drug Saf"},{"key":"8090_CR17","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1177\/009286150804200501","volume":"42","author":"M Lindquist","year":"2008","unstructured":"Lindquist M (2008) VigiBase, the WHO Global ICSR Database System: Basic Facts. Ther Innov Regul Sci 42:409\u2013419","journal-title":"Ther Innov Regul Sci"},{"issue":"2","key":"8090_CR18","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1016\/j.therap.2019.01.006","volume":"74","author":"JL Faillie","year":"2019","unstructured":"Faillie JL (2019) Case-non-case studies: Principle, methods, bias and interpretation. Therapie 74(2):225\u2013232","journal-title":"Therapie"},{"issue":"6","key":"8090_CR19","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1002\/pds.1742","volume":"18","author":"A Bate","year":"2009","unstructured":"Bate A, Evans SJ (2009) Quantitative signal detection using spontaneous ADR reporting. Pharmacoepidemiol Drug Saf 18(6):427\u2013436","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"4","key":"8090_CR20","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1056\/NEJMoa2508959","volume":"394","author":"SM Tolaney","year":"2026","unstructured":"Tolaney SM, de Azambuja E, Kalinsky K et al (2026) Sacituzumab Govitecan plus Pembrolizumab for Advanced Triple-Negative Breast Cancer. N Engl J Med 394(4):354\u2013366","journal-title":"N Engl J Med"},{"issue":"12","key":"8090_CR21","doi-asserted-by":"publisher","first-page":"1415","DOI":"10.1200\/JCO.22.02835","volume":"42","author":"P Grivas","year":"2024","unstructured":"Grivas P, Pouessel D, Park CH et al (2024) Sacituzumab Govitecan in Combination With Pembrolizumab for Patients With Metastatic Urothelial Cancer That Progressed After Platinum-Based Chemotherapy: TROPHY-U-01 Cohort 3. J Clin Oncol 42(12):1415\u20131425","journal-title":"J Clin Oncol"},{"issue":"3","key":"8090_CR22","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1200\/JCO.24.00920","volume":"43","author":"A Bardia","year":"2025","unstructured":"Bardia A, Jhaveri K, Im SA et al (2025) Datopotamab Deruxtecan Versus Chemotherapy in Previously Treated Inoperable\/Metastatic Hormone Receptor-Positive Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer: Primary Results From TROPION-Breast01. J Clin Oncol 43(3):285\u2013296","journal-title":"J Clin Oncol"},{"key":"8090_CR23","doi-asserted-by":"publisher","first-page":"1781533","DOI":"10.3389\/or.2026.1781533","volume":"20","author":"AA Sofianidi","year":"2026","unstructured":"Sofianidi AA, Papatheodoridi A, Dimitrakakis C, Marinopoulos S, Michalaki V, Zagouri F (2026) Sacituzumab tirumotecan (sac-TMT\/MK-2870\/SKB264): a novel antibody-drug conjugate in breast cancer. Oncol Rev 20:1781533 Published 2026 Feb 5","journal-title":"Oncol Rev"},{"issue":"1","key":"8090_CR24","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1056\/NEJMoa2203690","volume":"387","author":"S Modi","year":"2022","unstructured":"Modi S, Jacot W, Yamashita T et al (2022) Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer. N Engl J Med 387(1):9\u201320","journal-title":"N Engl J Med"}],"container-title":["Breast Cancer Research and Treatment"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-026-08090-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10549-026-08090-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-026-08090-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T14:11:22Z","timestamp":1790604682000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10549-026-08090-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,28]]},"references-count":24,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["8090"],"URL":"https:\/\/doi.org\/10.1007\/s10549-026-08090-5","relation":{},"ISSN":["0167-6806","1573-7217"],"issn-type":[{"value":"0167-6806","type":"print"},{"value":"1573-7217","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,28]]},"assertion":[{"value":"23 July 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 September 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study was approved by the ethics committee of University Hospital of Heraklion (number: 7948\/26-05-2025).","order":1,"name":"Ethics","label":"Ethical approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Patients included in this study have given informed consent to participate.","order":2,"name":"Ethics","label":"Consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"24"}}